Kiwi Wealth Investments Limited Partnership grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 4.3% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 54,895 shares of the biopharmaceutical company’s stock after buying an additional 2,269 shares during the quarter. Kiwi Wealth Investments Limited Partnership’s holdings in Gilead Sciences were worth $4,448,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Capital Asset Advisory Services LLC bought a new position in Gilead Sciences in the second quarter worth approximately $875,000. Factory Mutual Insurance Co. grew its stake in Gilead Sciences by 4.6% in the second quarter. Factory Mutual Insurance Co. now owns 586,000 shares of the biopharmaceutical company’s stock worth $41,477,000 after purchasing an additional 26,000 shares in the last quarter. Prentiss Smith & Co. Inc. bought a new position in Gilead Sciences in the second quarter worth approximately $497,000. Hellman Jordan Management Co. Inc. MA bought a new position in Gilead Sciences in the second quarter worth approximately $839,000. Finally, First American Bank grew its stake in Gilead Sciences by 19.9% in the second quarter. First American Bank now owns 74,301 shares of the biopharmaceutical company’s stock worth $5,259,000 after purchasing an additional 12,352 shares in the last quarter. 75.95% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently issued reports on GILD. Credit Suisse Group set a $80.00 price objective on Gilead Sciences and gave the stock a “hold” rating in a research note on Wednesday, January 3rd. Oppenheimer began coverage on Gilead Sciences in a research note on Thursday, October 5th. They issued a “market perform” rating on the stock. Mizuho increased their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. Leerink Swann increased their price objective on Gilead Sciences from $87.00 to $89.00 and gave the stock a “market perform” rating in a research note on Thursday, October 5th. Finally, BMO Capital Markets dropped their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Two equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating, sixteen have given a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $85.03.

Shares of Gilead Sciences, Inc. (NASDAQ:GILD) opened at $79.02 on Tuesday. Gilead Sciences, Inc. has a twelve month low of $63.76 and a twelve month high of $86.27. The company has a current ratio of 3.68, a quick ratio of 3.56 and a debt-to-equity ratio of 1.10. The company has a market capitalization of $103,190.00, a price-to-earnings ratio of 8.99, a PEG ratio of -1.68 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analyst estimates of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The business’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.75 EPS. sell-side analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.

The company also recently announced a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date was Thursday, December 14th. This represents a $2.08 dividend on an annualized basis and a yield of 2.63%. Gilead Sciences’s dividend payout ratio (DPR) is 23.66%.

In related news, insider John F. Milligan sold 220,000 shares of the firm’s stock in a transaction on Monday, November 13th. The stock was sold at an average price of $72.88, for a total value of $16,033,600.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of the firm’s stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $73.87, for a total value of $1,108,050.00. Following the completion of the transaction, the executive vice president now owns 64,613 shares of the company’s stock, valued at approximately $4,772,962.31. The disclosure for this sale can be found here. Insiders sold a total of 461,666 shares of company stock valued at $34,072,567 in the last 90 days. 1.30% of the stock is currently owned by company insiders.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/01/16/kiwi-wealth-investments-limited-partnership-has-4-45-million-stake-in-gilead-sciences-inc-gild.html.

Gilead Sciences Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.